Psychiatry Residents Journal Club

Journal club will be held once a month during our regular PRO time: Wednesdays at 1-2PM in NC5.710. Lunch will be served. Our faculty advisor is Dr. Byerly.

---

Journal Club #10
Date: June 10, 2009
Presenter: Felicia
Attending: Dr. Tirado

Description:
Dr. Carlos Tirado will be our guest attending. We'll be discussing a seminal paper in the substance abuse field - a JAMA article that lays out the argument for defining addiction as a chronic disease.

Download the article:

• McLellan et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95.

---

Journal Club #9
Date: May 13, 2009
Presenter: Jason
Attending: Dr. Byerly

Description:
We will be discussing the cost-effectiveness/Quality of Life evaluation from the CATIE trial. Dr. Byerly says: Not only does it have interesting findings, but it discusses the major issues considered in cost-effectiveness studies in general.

Download the article:

• Rosenheck et al. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. Am J Psychiatry 163:12, December 2006

---

Journal Club #8
Date: April 15, 2009
Presenter: Phil
Attending: Dr. Bylery

Description:
Genetics in mental health: we'll be discussing the landmark studies showing risk of depression with the serotonin transporter allele types. Dr. Byerly will be our guest attending.

Download the articles:

• Jacobs et al. Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry. 2006 Sep;63(9):989-96.
• Kendler et al. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry. 2005 May;62(5):529-35.

---

Journal Club #7
Date: March 11, 2009
Presenter: Sunil
Attending: Dr. Bylery

Description:
Dr. Bylerly returns as our guest attending as we discuss a landmark study that demonstrated that most of the weight-gain associated effects was due to Histamine-1 blockade - by using rodent models. It is a very undertstandable piece that also is of great clinical relevance.

Download the article:

• Kim et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007 Feb 27;104(9):3456-9.

---

Journal Club #6
Date: Feburary 11, 2009
Presenter: Maneesh
Attending: Dr. Kozel

Description:
Dr. Andy Kozel will be our guest attending as we discuss one of his recent papers on the neurobiology of deception. This session will be a good introduction to reading neuroimaging papers, as this study has elements of neuroimaging, clinical study, and developing a diagnostic test design.

Download the article:

• Kozel et al. (2009) Functional MRI Detection of Deception After Committing a Mock Sabotage Crime. J Forensic Sci, 54(1):220-231.

---

Journal Club #5
Date: January 14, 2009
Presenter: Tracy
Attending: Dr. Jarrett

Description:
An example of a well-designed psychotherapy trial. Dr. Robin Jarrett will be our guest attending.

Download the article:

• Jarrett et al. (1999) Treatment of atypical depression with cognitive therapy or phenelzine: A double-blind placebo controlled trial. Archives of General Psychiatry, 56, 431-437.

---

Journal Club #4
Date: December 10, 2008
Presenters: Felicia and Marisa
Attending: Dr. Trivedi

Description:
Two STAR*D papers on medication augmentation in depression. Dr. Trivedi will be our guest attending.

Download the articles:

• Rush et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEJM 2006 Mar 23;354(12):1231-42.
• Trivedi et al. Medication augmentation after the failure of SSRIs for depression. NEJM 2006 Mar 23;354(12):1243-52.

---

Journal Club #3
November 12, 2008
Presenter: Michelle
Attending: Dr. Bylery

Description:
Primary publication of CATIE results (Lieberman, NEJM, 2005). We will focus on design issues like patient population (unusually inclusive), medication dosing (which was arguably unfair for some of the treatments), and implications of the findings for clinical practice (that older agents performed as good as newer agents at 100-1000 X's less cost).

Download the article:

• Lieberman et al, NJEM, 2005

---

Download the articles

• Article 1a: (Kane, Arch Gen Psychiatry, 1988)
• Article 1b: (Bondolfi, Am J Psychiatry, 1988)

---

Journal Club #2
October 29, 2008
Presenters: Rachel
Attending: Dr. Bylery

Description:
We will be discussing article 1b as described above.

---

Journal Club #1
September 17, 2008
Presenters: Margaret and Rachel
Attending: Dr. Bylery

Description:
Two articles as a "set": First article: Classic Phase-III (premarketing) study of clozapine vs. chlorpromazine that led to clozapine's treatment-resistant FDA indication (Kane, Arch Gen Psychiatry, 1988). This study is frequently lauded for its outstanding, and "pure" efficacy design (quite different from CATIE). Second article: a Janssen-funded study (makers of Risperdal) of clozapine vs. risperidone (Bondolfi, Am J Psychiatry, 1988), which claims to compare cloz vs. risp in treatment -resistant schizophrenia. The 2nd article is a great example of how study design can be grossly manipulated to get the biased results a drug company might want .

---

<<Back to main page